JP2003527414A - Ｃ型肝炎を治療するための薬剤 - Google Patents

Ｃ型肝炎を治療するための薬剤

Info

Publication number
JP2003527414A
JP2003527414A JP2001568401A JP2001568401A JP2003527414A JP 2003527414 A JP2003527414 A JP 2003527414A JP 2001568401 A JP2001568401 A JP 2001568401A JP 2001568401 A JP2001568401 A JP 2001568401A JP 2003527414 A JP2003527414 A JP 2003527414A
Authority
JP
Japan
Prior art keywords
ukrain
patients
ifn
hepatitis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001568401A
Other languages
English (en)
Japanese (ja)
Inventor
ヴァジル ノヴィッキイ、
Original Assignee
ヴァジル ノヴィッキイ、
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァジル ノヴィッキイ、 filed Critical ヴァジル ノヴィッキイ、
Publication of JP2003527414A publication Critical patent/JP2003527414A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2001568401A 2000-03-22 2001-03-20 Ｃ型肝炎を治療するための薬剤 Pending JP2003527414A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0048100A AT408719B (de) 2000-03-22 2000-03-22 Mittel zur behandlung von hepatitis c
AT481/2000 2000-03-22
PCT/AT2001/000076 WO2001070203A2 (fr) 2000-03-22 2001-03-20 Agent de traitement de l'hepatite c

Publications (1)

Publication Number Publication Date
JP2003527414A true JP2003527414A (ja) 2003-09-16

Family

ID=3674939

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001568401A Pending JP2003527414A (ja) 2000-03-22 2001-03-20 Ｃ型肝炎を治療するための薬剤

Country Status (17)

Country Link
JP (1) JP2003527414A (fr)
KR (1) KR20020087045A (fr)
CN (1) CN1416347A (fr)
AT (1) AT408719B (fr)
AU (1) AU2001239000A1 (fr)
BG (1) BG107088A (fr)
BR (1) BR0107211A (fr)
CA (1) CA2389173A1 (fr)
EA (1) EA200200584A1 (fr)
HR (1) HRP20020367A2 (fr)
IL (1) IL149314A0 (fr)
IS (1) IS6360A (fr)
MA (1) MA25509A1 (fr)
MX (1) MXPA02004993A (fr)
NO (1) NO20022253L (fr)
PL (1) PL365000A1 (fr)
WO (1) WO2001070203A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106343303A (zh) * 2015-07-13 2017-01-25 张如安 灭杀乙肝病毒的饮料

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH695417A5 (de) * 2001-11-15 2006-05-15 Ddr Wassyl Nowicky Dipl Ing Verfahren zur Umsetzung von Alkaloiden.
EP1459753A1 (fr) 2003-03-18 2004-09-22 Nowicky, Wassyl, Dipl.-Ing. DDr. Dérivés quaternaires de chelidonine et d'alkaloides, procédé pour leur préparation et leur utilisation dans la préparation de médicaments
EP2083825A4 (fr) * 2006-09-26 2009-11-04 Addiction Res Inst Inc Compositions de traitement de l'hépatite c et procédés d'utilisation des compositions de traitement de l'hépatite c
CN106109538A (zh) * 2016-07-29 2016-11-16 桂林淮安天然保健品开发有限公司 治疗丙肝的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3128018A1 (de) * 1981-07-13 1983-04-07 Wassyl 1060 Wien Nowicky "verfahren zum diagnostizieren und fuer die therapeutische behandlung von tumoren und/oder infektioesen krankheiten verschiedenster art unter praeparativem einsatz von alkaloid-verbindungen bzw. deren salze"
US4970212A (en) * 1982-05-18 1990-11-13 Nowicky Wassili Method of treating human illnesses which compromise the ability to mount an effective immunological response
US4816462A (en) * 1982-05-18 1989-03-28 Nowicky Wassili Method for diagnosing and for the therapeutic treatment of tumors and/or infectious diseases of different types with alkaloid-compounds
PT93772A (pt) * 1989-04-17 1991-01-08 Searle & Co Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106343303A (zh) * 2015-07-13 2017-01-25 张如安 灭杀乙肝病毒的饮料

Also Published As

Publication number Publication date
NO20022253D0 (no) 2002-05-10
KR20020087045A (ko) 2002-11-21
AT408719B (de) 2002-02-25
WO2001070203A2 (fr) 2001-09-27
BG107088A (en) 2003-05-30
CA2389173A1 (fr) 2001-09-27
PL365000A1 (en) 2004-12-27
CN1416347A (zh) 2003-05-07
HRP20020367A2 (en) 2004-02-29
WO2001070203A3 (fr) 2002-09-06
BR0107211A (pt) 2004-01-06
NO20022253L (no) 2002-05-10
MXPA02004993A (es) 2003-10-14
IS6360A (is) 2002-04-24
IL149314A0 (en) 2002-11-10
AU2001239000A1 (en) 2001-10-03
ATA4812000A (de) 2001-07-15
EA200200584A1 (ru) 2003-06-26
MA25509A1 (fr) 2002-07-01

Similar Documents

Publication Publication Date Title
AU750026B2 (en) Product comprising at least a double stranded RNA combined with at least an antiviral agent
EA019965B1 (ru) Комбинация ингибитора протеазы ns3 hcv с интерфероном и рибавирином
JP2009502920A5 (fr)
JP2002539244A (ja) 成長促進用組成物
JP2010070566A (ja) ウイルス性肝炎の処置
JP2000507917A (ja) 持続的低用量サイトカイン注入治療
KR20050055053A (ko) 만성 Ｃ형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-α 및 리바비린의 용도
JP2009522371A5 (fr)
US20100266590A1 (en) Combination therapy
JP2018531945A (ja) 免疫系を刺激するためのペプチドの使用
TW201138773A (en) Dosage regimens for HCV combination therapy
JP2002527522A (ja) 慢性Ｃ型肝炎感染を有する患者における検出可能ＨＣＶ−ＲＮＡ根絶用リバビリン−インターフェロン−α併用療法
JP2007262082A (ja) 多発性硬化症の処置のためのリルゾールの使用
JP2003527414A (ja) Ｃ型肝炎を治療するための薬剤
JP2003507339A (ja) ＰＥＧ−ＩＦＮ−αと共同させたミコフェノラートモフェチル
CN116096383A (zh) 用于治疗丁型肝炎病毒感染的组合物和方法
AU2021271862A1 (en) TLR7/8 antagonists for the treatment of coronavirus infections
TW202146011A (zh) 治療b型肝炎病毒感染之組合療法
JP2003503457A (ja) 心臓血管合併症の治療用薬剤の製造におけるアンギオテンシンｉｉ１型受容体アンタゴニストの使用
JP2003519088A (ja) Ｈｉｖ感染患者の治療および予防のためのｇｓｓｇレダクターゼの使用
JP2000007578A (ja) Ｃ型肝炎ウイルスの陰性化のための投薬システム
CN111632150A (zh) 一种治疗肾病综合征的药物组合物
EP1305035A1 (fr) Analogues de naadp destines a moduler l'activite de lymphocytes t
US7728033B2 (en) Mycophenolate mofetil in diabetic nephropathy
WO2005027910A1 (fr) Procede de traitement du gene de la leucemie a lignee mixte-rearrangee en leucemies lymphoblastiques aigues